Acetazolamide & Atomoxetine Improve Hypoventilation in Obesity-Hypoventilation Syndrome

A combination of acetazolamide and atomoxetine shows promise as a potential therapy for adults with obesity-hypoventilation syndrome (OHS), particularly those who cannot tolerate continuous positive airway pressure (CPAP) therapy, according to a recent study published in CHEST. The two-week trial demonstrated improvements in nocturnal carbon dioxide levels and sleep-related breathing in treatment-naive patients.

Understanding Obesity-Hypoventilation Syndrome

Obesity-hypoventilation syndrome is a condition where individuals with obesity experience reduced breathing effort during sleep, leading to elevated carbon dioxide levels in the blood. This can result in daytime sleepiness, fatigue and an increased risk of cardiovascular problems. Current treatment primarily relies on CPAP, a machine that delivers continuous airflow to retain the airways open, but many patients find it uncomfortable or difficult to adhere to long-term. Elisa Perger, MD, PhD, of the sleep disorder center at San Luca Hospital in Italy, explained that this research explores a pharmacological approach to address the underlying mechanisms of OHS.

Study Details and Findings

The randomized, double-blinded, placebo-controlled study involved 13 adults with OHS who had not previously received CPAP treatment. Participants received either a combination of 500 mg of acetazolamide and 100 mg of atomoxetine daily or a placebo for two weeks, followed by a washout period and a switch to the alternate treatment. Acetazolamide is a carbonic anhydrase inhibitor often used to treat glaucoma and altitude sickness, while atomoxetine is a selective norepinephrine reuptake inhibitor typically prescribed for attention-deficit/hyperactivity disorder (ADHD).

Researchers found that the combination therapy significantly reduced nocturnal carbon dioxide levels by an average of 5.8 mm Hg compared to placebo (95% CI, –7.8 to –3.7 mm Hg). A greater proportion of patients in the drug combination group (6 out of 13) experienced a decrease in sleep-related hypoventilation compared to the placebo group (1 out of 13; OR = 0.097; 95% CI, 0.01-0.983). The study also reported a significant reduction in the apnea-hypopnea index (AHI) – a measure of sleep apnea severity – by 20.9 events/hour with the drug combination.

How the Drugs May Operate

Dr. Perger and colleagues hypothesized that the combination targets two key factors contributing to OHS: a blunted ventilatory drive (the body’s signal to breathe) and upper airway collapsibility. Acetazolamide may enhance ventilatory drive by increasing carbon dioxide sensitivity, while atomoxetine could potentially improve upper airway muscle tone. As detailed in the CHEST publication, the researchers noted that this approach aims to address the physiological basis of OHS rather than solely relying on mechanical support like CPAP.

Important Caveats and Limitations

It’s crucial to emphasize that this is a proof-of-concept study with a small sample size. The findings need to be replicated in larger, more diverse populations to confirm their effectiveness and safety. The study duration of only two weeks also limits the ability to assess the long-term benefits and potential side effects of the drug combination. The study population consisted of treatment-naive patients, so it’s unclear whether the same results would be observed in individuals who have previously tried and failed CPAP therapy.

The researchers also observed some side effects, including dysgeusia (altered taste) and paresthesia (tingling or numbness). Metabolic acidosis was noted in four patients, though it wasn’t associated with typical symptoms. Acetazolamide has been previously studied in combination with other medications for sleep apnea, but the specific combination with atomoxetine is novel and requires further investigation.

What This Means for Patients

While these findings are encouraging, it’s important to remember that the acetazolamide-atomoxetine combination is not currently approved for the treatment of OHS. Patients should not attempt to self-treat with these medications. The study highlights the need for a more personalized approach to OHS management, considering individual patient characteristics and underlying pathophysiological mechanisms.

The Path Forward

Dr. Perger suggests that future research should focus on identifying which patient subgroups are most likely to benefit from this dual-mechanism therapy. Larger clinical trials are needed to evaluate the long-term efficacy, safety, and optimal dosing of the drug combination. Researchers also plan to investigate the impact of this therapy on patient-centered outcomes, such as symptom burden, functional capacity, and cardiovascular events. The American Academy of Sleep Medicine cautions about electrolyte disturbances and acid-base imbalances with acetazolamide in patients with cardiac comorbidities, so careful monitoring will be essential in future studies and potential clinical employ.

The study’s findings represent a step toward expanding the therapeutic options for OHS, offering hope for patients who struggle with CPAP intolerance. However, further research is essential to fully understand the potential benefits and risks of this novel treatment approach.